En español
NIDA

Menu

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)

This study will assess the comparative effectiveness of extended release injectable naltrexone (XR-NTX) versus buprenorphine-naloxone (BUP-NX) as pharmacotherapeutic aids to recovery amongst treatment-seeking heroin- and/or prescription opioid-dependent participants.  The primary goal of the study is to estimate the difference, if one exists, between XR-NTX and BUP-NX in the distribution of the time to relapse during the 6-month trial.

CTN Protocol ID: 
CTN-0051
Enrollment Status: 
Pending
Principal Investigator(s)
John Rotrosen, M.D.
Professor
NYU School of Medicine
Department of Psychiatry
423 East 23rd Street, 17W
New York, NY 10010
john.rotrosen@nyumc.org

    Attention

    Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at

    Looking for Treatment?

    Use the SAMHSA Treatment Locator or 1-800-662-HELP.

    Helpline open during government shutdown

    Featured Publication

    Featured Publication

    Drugs, Brains, and Behavior - The Science of Addiction

    As a result of scientific research, we know that addiction is a disease that affects both brain and behavior.

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.